Moreover, this suggests a stepwise process of PAX5 inactivation during leukemia development, clearly recapitulated in familial BCP-ALL cases with heterozygous PAX5 germline variants, including PAX5 p.G183S [15, 16] and PAX5 p.R38H [17, 18]. Here, PAX5 is linked to leukemia.